HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LH
Labcorp Holdings Inc.
LH's fundamentals are mixed, but it looks expensive: trading at 31x earnings, above its usual 25x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
LH's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $136 | -63% |
| Forward | 19x | $372 | — |
| Fair | 24x | $296 | -20% |
| Current | 31x | $372 | — |
| Expensive | 41x | $500 | +34% |
Historical ranges are pointers, not guarantees.
LH's PE is in its expensive range at 31x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its fair range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
LH has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
LH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.25 | +58% |
| Q3 2026 | $12.19 | +20% |
| Q2 2026 | $12.09 | +33% |
| Q1 2026 | $11.29 | +30% |
| Q4 2025 | $10.46 | +18% |
| Q3 2025 | $10.20 | +94% |
| Q2 2025 | $9.08 | +69% |
| Q1 2025 | $8.67 | +71% |
| Q4 2024 | $8.84 | +85% |
LH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
LH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.8B | +6.9% |
| Q2 2026 | $3.7B | +5.8% |
| Q1 2026 | $3.5B | +5.8% |
| Q4 2025 | $3.5B | +5.6% |
| Q3 2025 | $3.6B | +8.6% |
| Q2 2025 | $3.5B | +9.5% |
| Q1 2025 | $3.3B | +5.3% |
| Q4 2024 | $3.3B | +9.8% |
LH's revenue has grown year over year for 10 quarters in a row: $3.8B last quarter, up 6.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -0.6 points |
| Q2 2026 | 12% | +0.9 points |
| Q1 2026 | 11% | +1 points |
| Q4 2025 | 7.6% | +1.1 points |
| Q3 2025 | 11% | +3.4 points |
| Q2 2025 | 11% | +2 points |
| Q1 2025 | 9.8% | -0.4 points |
| Q4 2024 | 6.5% | +11 points |
LH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over LH on cash flow, with more consistent year-over-year improvement.
LH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $412.2M | +47% |
| Q2 2026 | $313.9M | -42% |
| Q1 2026 | $70.5M | +$178M |
| Q4 2025 | $490.3M | -26% |
| Q3 2025 | $280.5M | +74% |
| Q2 2025 | $542.7M | +25% |
| Q1 2025 | -$107.5M | +$56.1M |
| Q4 2024 | $665.1M | +61% |
LH still generates free cash flow, though less than at its 2021 peak: $1.3B over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -400K shares |
| 1 year | -2.5% | -2.1M shares |
| 3 years | -6.2% | -5.4M shares |
| 5 years | -16% | -15.5M shares |
| Available history | -17% | -17M shares |
LH has 82M diluted shares, down 2.5% from a year ago, with $677M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $353.8M |
| Q1 2026 | $98M |
| Q4 2025 | $225M |
| Q3 2025 | $25M |
| Q4 2024 | $75.1M |
| Q3 2024 | $75M |
| Q4 2023 | $9M |
LH spent $677M buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.5x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 3.0x | Moderate |
| Q4 2024 | 2.8x | Moderate |
LH's net debt is about 2.5 years of its operating earnings (EBITDA), up from 2.2 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.6 | Overbought |
| Stochastic | 91.4 | Overbought |
LH's weekly RSI is 75 (overbought) and its Stochastic is 91 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LH PE vs Healthcare Sector
| Metric | LH | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 26x | 18% above |
| PE % | 77 | 29 | 48 pts above |
LH is trading at 31x earnings, a 18% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $334.7 | 11% above |
| 20 week MA | $319.9 | 16% above |
| 50 week MA | $286.8 | 30% above |
| 100 week MA | $270.3 | 38% above |
| 200 week MA | $240.9 | 55% above |
LH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
LH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $145.5 | $175.1 | +20% |
| 2021 | $175.1 | $259.4 | +48% |
| 2022 | $259.4 | $199.0 | -23% |
| 2023 | $199.0 | $227.3 | +14% |
| 2024 | $227.3 | $230.4 | +1.4% |
| 2025 | $230.4 | $253.9 | +10% |
| 2026 YTD | $253.9 | $372.3 | +47% |
LH has the edge over HIMS on returns for 2026, with the stronger performance.